June 3, 2025
BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback
BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases
Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025
Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial
OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025
OSE Immunotherapeutics; Tedopi; ASCO 2025; pancreatic cancer; neo-epitope cancer vaccine; phase 2; overall survival rate
Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal
Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments
Kymera Soars on Early Protein Degrader Data
Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease
Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound
Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma
Sanofi Increases Investment in Nurix-Partnership for STAT6 Program
Sanofi; Nurix Therapeutics; STAT6; NX-3911; protein degrader; atopic dermatitis; asthma; drug discovery; licensing deal; DEL-AI platform; biotech collaboration
ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo
ASCO 2025; Amgen; Imdelltra; tarlatamab-dlle; lung cancer; small cell lung cancer; death risk reduction; overall survival; Phase 3 trial
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus
Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline